BSEResult2d ago · 13 Nov 2026, 01:33 pm

Outcome of Board Meeting held on Friday, November 13, 2026 at 12.00 Noon through video conferencing for approval of unaudited Standalone & Consolidated Financial Results for the half year ended September 30, 2026

Clinitech Laboratory Ltd · 544220

✦ AI SummaryResults

The Board of Directors of Clinitech Laboratory Ltd approved the unaudited standalone and consolidated financial results for the half year ended September 30, 2026, along with a limited review report. The company also considered the utilization of IPO proceeds and noted the internal audit report for the same period.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Clinitech Laboratory Ltd - 544220 - Unaudited Standalone & Consolidated Financial Results For The Half Year Ended September 30, 2026

Attachments (1)

📄

f174db28-5a1a-460f-83e0-8e5e9276e392.pdf

pdf

Download →
View document text
Date: November 13, 2026. Asst. General Manager, Dept. of Corporate Services, BSE Limited 1st Floor, P.J. Towers, Dalal Street, Fort, Mumbai: 400001. Sub: Outcome of the Board Meeting held on November 13, 2026. Reference: CLINITECH LABORATORY LIMITED (CTLLAB) Scrip Code: 544220. We hereby inform that the Board of Directors of the company, at its meeting held today i.e., November 13, 2026, have:  Approved the Un-Audited Standalone & Consolidated Financial Result of the Company along with Limited Review Report (LRR) for the half year ended September 30, 2026;  Considered and noted utilization of IPO Proceeds  Took note of Internal Audit report for the half year ended September 30, 2026. In connection with Point No. 1, please find enclosed the copy of Un-Audited Standalone & Consolidated financial Results of the Company along with Limited Review Report (LRR) for the half year ended September 30, 2026 by the Statutory Auditors of the Company as “Annexure-I” and copy of certificate indicating the utilization of the issue proceeds certified by Statutory Auditor as required pursuant to circular no. NSE/CML/2024/23 as ‘Annexure – II’ The meeting commenced at 12.00 Noon (IST) and concluded at 01.00 P.M (IST) Kindly take the note of the above. Thanking you, Yours faithfully, For CLINITECH LABORATORY LIMITED Jagdish Umakant Nayak Chairman and Managing Director DIN: 00646672 Encl: as above